Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

858 - A systematic review and meta-analysis of the distress thermometer for the screening of distress in Chinese patients with cancer

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Hui Hui Sun

Citation

Annals of Oncology (2019) 30 (suppl_5): v829-v835. 10.1093/annonc/mdz275

Authors

H.H. Sun

Author affiliations

  • Medical Oncology, Tongji Medical College Huazhong University of Science and Technology, 430030 - Wuhan/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 858

Background

Screening and management of distress are essential. The Distress thermometer (DT) is a common screening tool However, it’s cutoff score and the accuracy properties such as sensitivity and specificity is still unclear in Chinese cancer patients.

Methods

A systematic search was conducted in PubMed, Embase, Cochrane Library, CNKI, Wanfang and VIP databases. Four tabular data were extracted, then pooled sensitivity, specificity, positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR) were calculated. The area under the curve (AUC) was summarized from receiver operating characteristic (SROC) curves with Meta-Disc version 1.4and publication bias with STATA 12.0 software.

Results

Seven publications describing 2515 Chinese cancer patients were included and six studies of 1919 samples comparing the DT with the Hospital Anxiety and Depression Scale-Total (HADS-T) were merged in the meta-analysis. The optimal cut-off score of 4 shows the balance between the pooled sensitivity (0.74, 95%CI 0.71-0.77) and pooled specificity (0.85, 95%CI 0.83-0.87), while the AUC of SROC is 0.88.

Conclusions

The DT with the cut-off score 4, is an effective screening tool in Chinese patients with cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.